GlaxoSmithKline switches to Microsoft Online


GlaxoSmithKline switches to Microsoft Online

Cliff Saran

Pharmaceutical giant GlaxoSmithKline has become one of the first businesses to standardise on Microsoft's Online Services, launched earlier today.

The company is planning to replace its Plumtree portal at Lotus Notes infrastructure with Microsoft Online Services, including Exchange Online, SharePoint Online, Office Communications Online, and Office Live Meeting.

GSK said the Microsoft software will be used to support collaboration across the company and improve productivity for its global community of more than 100,000 users in over 100 countries.

Ingo Elfering, vice-president of ITstrategy at GlaxoSmithKline, who has run a pilot with the Microsoft software, wrote in a blog posting, "We are able to reduce our IT operational costs by roughly 30% of what we are spending now and introduce a variable cost subscription model for these technologies that allows us to more rapidly scale or divest our investment as necessary as we undergo a transformational change in the pharmaceutical industry."

Microsoft Online Services includes Exchange Online, SharePoint Online, Office Communications Online, Office Live Meeting and Deskless Worker Suite, which provides thin client access to Microsoft Office software.

Microsoft said businesses can subscribe to Exchange Online, SharePoint Online, Office Communications Online and Office Live Meeting individually, or together as the Business Productivity Online Suite, which costs £10.04 pounds per month per user. Microsoft said businesses save 38% buying the suite, compared with subscribing separately to the individual services.

Email Alerts

Register now to receive IT-related news, guides and more, delivered to your inbox.
By submitting your personal information, you agree to receive emails regarding relevant products and special offers from TechTarget and its partners. You also agree that your personal information may be transferred and processed in the United States, and that you have read and agree to the Terms of Use and the Privacy Policy.

COMMENTS powered by Disqus  //  Commenting policy